Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
RYCEF
-0.0200
Berliner Boersenzeitung - Novo Nordisk to slash prices of weightloss drugs in US
EUR
-
AED 4.234162
AFN 75.520719
ALL 93.601185
AMD 421.871235
ANG 2.063555
AOA 1057.24245
ARS 1720.50819
AUD 1.631861
AWG 2.075286
AZN 1.958757
BAM 1.95465
BBD 2.321834
BDT 141.96768
BGN 1.956177
BHD 0.434715
BIF 3447.856524
BMD 1.152936
BND 1.475019
BOB 13.597116
BRL 5.991582
BSD 1.152822
BTN 109.838311
BWP 15.518732
BYN 3.442944
BYR 22597.554879
BZD 2.318556
CAD 1.607119
CDF 2622.929869
CHF 0.937372
CLF 0.026792
CLP 1054.464094
CNY 7.77523
CNH 7.775824
COP 3629.340254
CRC 523.691797
CUC 1.152936
CUP 30.552817
CVE 110.681377
CZK 24.231263
DJF 204.89978
DKK 7.475761
DOP 67.308837
DZD 153.22017
EGP 57.898976
ERN 17.294047
ETB 184.441064
FJD 2.550814
FKP 0.853229
GBP 0.854055
GEL 3.008945
GGP 0.853229
GHS 13.163237
GIP 0.853229
GMD 85.317165
GNF 10119.900208
GTQ 8.795747
GYD 241.230123
HKD 9.046579
HNL 30.985192
HRK 7.535826
HTG 150.789949
HUF 364.476076
IDR 20590.292479
ILS 3.434712
IMP 0.853229
INR 109.926555
IQD 1510.923248
IRR 1584855.300116
ISK 141.995699
JEP 0.853229
JMD 182.504176
JOD 0.817406
JPY 183.68928
KES 149.051317
KGS 100.82421
KHR 4676.310481
KMF 493.456944
KPW 1037.642491
KRW 1630.690189
KWD 0.356419
KYD 0.960726
KZT 536.769445
LAK 26001.617499
LBP 103399.458106
LKR 385.353212
LRD 209.402074
LSL 18.63091
LTL 3.404322
LVL 0.6974
LYD 7.338458
MAD 10.729807
MDL 19.984066
MGA 4966.272299
MKD 61.551238
MMK 2421.093744
MNT 4146.726689
MOP 9.317997
MRU 46.244457
MUR 54.268822
MVR 17.824178
MWK 2002.650688
MXN 19.663331
MYR 4.710444
MZN 73.665386
NAD 18.631039
NGN 1571.994494
NIO 42.4254
NOK 10.942001
NPR 175.73805
NZD 1.967693
OMR 0.443314
PAB 1.152832
PEN 3.873288
PGK 5.078668
PHP 70.611589
PKR 320.296049
PLN 4.305353
PYG 6879.011227
QAR 4.203318
RON 5.234906
RSD 117.338942
RUB 95.57845
RWF 1692.510743
SAR 4.322078
SBD 9.298365
SCR 15.89971
SDG 692.337385
SEK 11.041438
SGD 1.475407
SHP 0.854171
SLE 28.304309
SLL 24176.498606
SOS 658.917496
SRD 43.431291
STD 23863.457231
STN 24.788134
SVC 10.087151
SYP 14990.479632
SZL 18.619683
THB 38.127806
TJS 10.663617
TMT 4.035278
TND 3.386164
TOP 2.775995
TRY 55.084073
TTD 7.818466
TWD 37.145339
TZS 3055.279336
UAH 51.510838
UGX 4276.483203
USD 1.152936
UYU 46.403093
UZS 13786.814399
VES 882.455268
VND 30033.418665
VUV 136.557029
WST 3.147505
XAF 655.5655
XAG 0.017595
XAU 0.000261
XCD 3.115868
XCG 2.077677
XDR 0.815016
XOF 654.868115
XPF 119.331742
YER 273.418516
ZAR 18.602025
ZMK 10377.812955
ZMW 21.696419
ZWL 371.245074
- Venezuela govt, opposition wrap up round of post-Maduro talks
- Matthew McConaughey on his sweet return to the big screen
- Five things to know about Zambia as it goes to the polls
- President's economic record on the line as Zambia votes
- Nakashima holds off Jodar to book first ATP Masters final in Montreal
- Spain darkens as solar eclipse races south from Arctic
- Grieving Messi available for Miami in Leagues Cup clash
- Trump 'low-key' bets on economic pressure against Iran
- Colombia enters 'final phase' of quake search as toll hits 265
- Pitch invaders take selfies with Fernandes during Man Utd friendly
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
(O.Joost--BBZ)
